Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Thymic Carcinoma
Regimen:
VIP (cisplatin + etoposide IV + ifosfamide)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Thymic Carcinoma: FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS...Other Recommended…Etoposide/ifosfamide/cisplatin...Etoposide 75 mg/m2 on days 1–4; Ifosfamide 1.2 g/m2 on days 1–4; Cisplatin 20 mg/m2 on days 1–4...Administered every 3 weeks...
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login